12 Best Psychedelic Stocks to Buy in 2025

4. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Number of Hedge Fund Holders: 55 

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. Its flagship drug, Caplyta (lumateperone), is approved for schizophrenia and bipolar depression in adults. The company generates revenue mainly from Caplyta sales, along with income from research collaborations and licensing agreements. It is also developing ITI-1549, a non-hallucinogenic psychedelic designed to treat mood disorders by targeting 5-HT2A receptors while avoiding hallucinogenic effects and cardiac risks. Preclinical studies suggest ITI-1549 enhances neuroplasticity, increases social interaction, and reduces anxiety and depressive symptoms.

Johnson & Johnson’s announcement that it would buy Intra-Cellular Therapies for $14.6 billion in cash at $132 per share caused the stock to spike in 2025.

Sales of Caplyta at Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) continued to rise sharply. The business reported net product sales of $175.2 million for the third quarter of 2024, a 39% increase over the same period in 2023. Total revenue for the quarter reached $175.4 million, with a net loss of $26.3 million.